Featured in CardioExchange: Heart Failure Trial Stopped Early Because of Significant Drop in Cardiovascular Mortality

By Larry Husten

The largest-ever trial in heart failure has been stopped early because of a highly statistically significant reduction in cardiovascular mortality, according to one of the trial's two primary investigators. PARADIGM-HF tested LCZ696, a novel, first-in-class angiotensin receptor neprilysin inhibitor.